Onderzoeker
Valerie Fonteyne
- Trefwoorden:radiotherapie, prostaatkanker, blaaskanker
- Disciplines:Morfologische wetenschappen
Affiliaties
- Vakgroep Structuur en Herstel van de Mens (Departement)
Lid
Vanaf1 okt 2018 → Heden - Vakgroep Radiotherapie en Experimenteel Kankeronderzoek (Departement)
Lid
Vanaf1 okt 2015 → 30 sep 2018
Projecten
1 - 1 of 1
- Het combineren cystectomie en externe beam radiotherapie voor patiënten met spier-invasieve blaaskanker: een fase II studieVanaf1 okt 2016 → 30 sep 2021Financiering: VZW en equivalenten
Publicaties
1 - 10 van 21
- Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy : real-world data from the E2-RADIatE OligoCare cohort(2024)
Auteurs: Renée Bultijnck, Mieke Van Hemelrijck, Valerie Fonteyne, Lorenzo Livi, Barbara Alicja Jereczek-Fossa, Hossein Hemmatazad, Michael Mayinger, Heike Peulen, Luc Verbeke, Sara Ramella, et al.
- Experiences of men with prostate cancer participating in a clinical pathway with a supervised group-based exercise program to combat androgen deprivation-induced side effects : a qualitative focus group study(2023)
Auteurs: Renée Bultijnck, Elke Rammant, Karel Decaestecker, Valerie Fonteyne, Nicolaas Lumen, Piet Ost, Benedicte Deforche
- Comparing symptom reporting by prostate cancer patients and healthcare professionals in the international multicentre REQUITE study(2023)
Auteurs: Philipp Heumann, Miguel E. Aguado-Barrera, Barbara Avuzzi, David Azria, Erik Briers, Renée Bultijnck, Ananya Choudhury, Dirk De Ruysscher, Marie-Pierre Farcy-Jacquet, Valerie Fonteyne, et al.
- Microbiome and metabolome dynamics during radiotherapy for prostate cancer(2023)
Auteurs: Willeke Danckaert, Mathieu Spaas, Nora Sundahl, Aurélie De Bruycker, Valerie Fonteyne, Ellen De Paepe, Carlos De Wagter, Lynn Vanhaecke, Piet Ost
- Large-scale meta–genome-wide association study reveals common genetic factors linked to radiation-induced acute toxicities across cancer types(2023)
Auteurs: Elnaz Naderi, Miguel E Aguado-Barrera, Line M H Schack, Leila Dorling, Tim Rattay, Laura Fachal, Holly Summersgill, Laura Martínez-Calvo, Ceilidh Welsh, Tom Dudding, et al.
- WNT pathway mutations in metachronous oligometastatic castration-sensitive prostate cancer(2023)
Auteurs: Philip Sutera, Matthew P. Deek, Kim Van der Eecken, Amol C. Shetty, Jin Hee Chang, Theresa Hodges, Yang Song, Sofie Verbeke, Jo Van Dorpe, Valerie Fonteyne, et al.
Pagina's: 1095 - 1101 - High weekly integral dose and larger fraction size increase risk of fatigue and worsening of functional outcomes following radiotherapy for localized prostate cancer(2022)
Auteurs: Nuradh Joseph, Alessandro Cicchetti, Alan McWilliam, Adam Webb, Petra Seibold, Claudio Fiorino, Cesare Cozzarini, Liv Veldeman, Renée Bultijnck, Valerie Fonteyne, et al.
- Physical activity and health-related quality of life from diagnosis to one year after radical cystectomy in patients with bladder cancer : a longitudinal cohort study(2022)
Auteurs: Elke Rammant, Ann Van Hecke, Jelle Van Cauwenberg, Karel Decaestecker, Lindsay Poppe, Beth Russel, Renée Bultijnck, Maarten Albersen, Sofie Verhaeghe, Mieke Van Hemelrijck, et al.
Pagina's: 395 - 404 - Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer(2022)
Auteurs: Sarah L. Kerns, Ashley Amidon Morlang, Sharon M. Lee, Derick R. Peterson, Brian Marples, Hong Zhang, Kevin Bylund, Doug Rosenzweig, William Hall, Kim De Ruyck, et al.
Pagina's: 75 - 82 - A trial-based cost-utility analysis of metastasis-directed therapy for oligorecurrent prostate cancer(2020)
Auteurs: Elise De Bleser, Ruben Willems, Karel Decaestecker, Lieven Annemans, Aurélie De Bruycker, Valerie Fonteyne, Nicolaas Lumen, Filip Ameye, Ignace Billiet, Steven Joniau, et al.